文献速递生殖医学

澳大利亚IVF患者附加项目使用普遍性及决策调查

How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究通过社交媒体对2017年以来在澳大利亚接受IVF的女性进行在线调查,分析1590份有效问卷发现,82%的女性使用过至少一种IVF附加项目,最常见为针灸、胚胎非整倍体遗传学检测和中药。多数附加项目需额外付费(72%),54%的女性从生育专家处了解附加项目,66%的女性对使用附加项目的决定感到后悔,且在IVF未成功或认为专家对决策影响更大的女性中后悔更严重。

要点

  • 82%的澳大利亚IVF女性使用过至少一种附加项目,72%需额外付费。
  • 54%的女性从生育专家处了解附加项目,多数认为决策与专家共同做出。
  • 66%的女性对使用附加项目的决定有后悔,IVF未成功者后悔更严重(83%)。

核心结论

  • 澳大利亚IVF附加项目使用率很高(82%),但多数附加项目缺乏安全性和有效性的有力证据,患者可能未充分知晓风险与获益。

研究设计与样本

  • 在线调查通过社交媒体发放给2017年以来在澳大利亚接受IVF的女性,排除代孕、供卵刺激或仅冻卵者,调查开放时间为2020年6月21日至7月14日,共分析1590份有效问卷。

主要发现

  • 82%的女性使用过一种或多种附加项目,最常见为针灸、胚胎非整倍体遗传学检测和中药。
  • 72%的附加项目产生额外费用,54%的女性从生育专家处了解附加项目,多数报告决策与专家同等共享。
  • 女性高度重视安全性和有效性的科学证据,49%假设附加项目已知安全。
  • 66%的女性对使用附加项目的决定有一定后悔,IVF未成功者后悔更严重(83%),认为专家对决策贡献更大者后悔也更严重(75%)。

临床怎么用

  • 临床医生应向IVF患者充分告知附加项目缺乏有力证据的现状及额外费用,促进共同决策以减少决策后悔。

局限性

  • 回顾性调查依赖患者回忆,决策贡献等方面易产生偏倚,结果可能与直接从IVF诊所或生育专家收集的数据不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the prevalence and pattern of IVF add-on use in Australia? SUMMARY ANSWER: Among women having IVF in the last 3 years, 82% had used one or more IVF add-on, most commonly acupuncture, preimplantation genetic testing for aneuploidy and Chinese herbal medicine. WHAT IS KNOWN ALREADY: IVF add-ons are procedures, techniques or medicines which may be considered nonessential to IVF, but usually used in attempts to improve the probability of conception and live birth. The use of IVF add-ons is believed to be widespread; however, there is little information about the prevalence and patterns of use in different settings. STUDY DESIGN, SIZE, DURATION: An online survey was distributed via social media to women in Australia who had undergone IVF since 2017. Women were excluded if they were gestational surrogates, used a surrogate, or underwent ovarian stimulation for oocyte donation or elective oocyte cryopreservation only. The survey was open from 21 June to 14 July 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Survey questions included demographics, IVF and medical history, and use of IVF add-ons including details of the type of add-on, costs and information sources used. Participants were also asked about the relative importance of evidence regarding safety and effectiveness, factors considered in decision-making and decision regret. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1590 eligible responses were analysed. Overall, 82% of women had used one or more add-ons and these usually incurred an additional cost (72%). Around half (54%) had learned about add-ons from their fertility specialist, and most reported that the decision to use add-ons was equally shared with the specialist. Women placed a high level of importance on scientific evidence for safety and efficacy, and half (49%) assumed that add-ons were known to be safe. Most women experienced some regret at the decision to use IVF add-ons (66%), and this was more severe among women whose IVF was unsuccessful (83%) and who believed that the specialist had a larger contribution to the decision to use add-ons (75%). LIMITATIONS, REASONS FOR CAUTION: This retrospective survey relied on patient recall. Some aspects were particularly prone to bias such as contributions to decision-making. This approach to capturing IVF add-on use may yield different results to data collected directly from IVF clinics or from fertility specialists. WIDER IMPLICATIONS OF THE FINDINGS: There is a very high prevalence of IVF add-on use in Australia which may be generalisable to other settings with similar models of IVF provision. Although women placed high importance on scientific evidence to support add-ons, most add-ons do not have robust evidence of safety and effectiveness. This suggests that IVF patients are not adequately informed about the risks and benefits of IVF add-ons, or are not aware of the paucity of evidence to support their use. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a McKenzie Postdoctoral Fellowship Grant (University of Melbourne), a Department of Obstetrics and Gynaecology Innovation Grant (University of Melbourne) and an NHMRC Investigator Grant (APP1195189). A.P. declares that he provides fertility services at Melbourne IVF (part of Virtus Health). J.W. reports grants from Wellcome Trust, during the conduct of the study, and that publishing benefits his career. The remaining authors report no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lensen S, Hammarberg K, Polyakov A, et al. How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients. Hum Reprod. 2021. PMID: 33942073. doi:10.1093/humrep/deab098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。